Feasibility of Estimating the Prevalence of Malnutrition, Frailty and Sarcopenia in Older People in UK Biobank, Cross-sectional Study: A Study Protocol

Sponsor
University of Manchester (Other)
Overall Status
Completed
CT.gov ID
NCT04655456
Collaborator
(none)
381,000
1
163.7
2327.7

Study Details

Study Description

Brief Summary

Background: measuring the prevalence of malnutrition, frailty and sarcopenia in same group of older adults is effective in understanding the relation between these conditions. This could support diagnosing, treatment and prevention in future practice. The research is aiming to measure the estimate prevalence of malnutrition, frailty, sarcopenia and their overlap in older adults, using the UK Biobank. In addition, it will aim to compare the two models of frailty the phenotype and deficit accumulation using the UK Biobank database, as data comparing these models is limited.

Methods/design: This is a cross-sectional study design that will use the UK Biobank database, which includes 381,000 participants males and females, aged 50 years and above, who completed the UK Biobank baseline assessments were included that is a subset from the main sample size from the UK Biobank. For baseline, details of participant's characteristics will be included. All three conditions will be identified as malnutrition by using GLIM criteria, while frailty by using two models; the first model will be the 36 deficits model and phenotype model. Finally, sarcopenia condition will be judge according to EWGSOP standard. All these models will be determining the feasibility to apply it using the available database in the UK Biobank.

Discussion: This proposed study will help in understanding the relation between malnutrition, frailty and sarcopenia. As in worldwide, there is little published research on the overlap between malnutrition, frailty and sarcopenia. Despite definitions and diagnostic criteria were developed for these conditions. There is conflict extend to the definitions and identification criteria's. This study will use UK Biobank database to measuring the estimate prevalence in older people and determine the overlap between three conditions.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    The UK Biobank is a population-based study of a large prospective longitudinal cohort with information on 500,000 people, who were aged 40-69 when recruited in 2006-2010 from England, Scotland and Wales. The database includes demographic data, online questionnaires, X-rays and scan image of (brain, heart, abdomen, bones and carotid artery), as well as urine and saliva samples and blood biochemistry including: hormones and blood lipid. The online questionnaires (about: diet, cognitive function, work history and digestive health). It aims to improve the following: prevention, diagnosis and treatment for a broad number of diseases including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. This detailed information on participants provide a resource for investigators to conduct research related a particular diseases.

    There are four phases of assessment in UK Biobank. The first phase was the UK Biobank Pilot assessment that included 3798 participants from Stockport only in 2006. Then, the second phase was the initial assessment visit that started in 2007 until 2010. This was the baseline assessment and included approximately 500000 participants. After that, the third phase was conducted and called the first repeat assessment visit which took place between 2012-2013 and included 20346 participants. Lastly, the imaging visit which is considered the fourth phase started in 2014 until present.

    Study Design

    Study Type:
    Observational [Patient Registry]
    Actual Enrollment :
    381000 participants
    Observational Model:
    Other
    Time Perspective:
    Cross-Sectional
    Official Title:
    Feasibility of Estimating the Prevalence of Malnutrition, Frailty and Sarcopenia in Older People in UK Biobank, Cross-sectional Study: A Study Protocol
    Actual Study Start Date :
    Apr 1, 2007
    Actual Primary Completion Date :
    Nov 20, 2020
    Actual Study Completion Date :
    Nov 20, 2020

    Outcome Measures

    Primary Outcome Measures

    1. Determine the feasibility of obtaining variables to be able to determine malnutrition, frailty and sarcopenia in the UK Biobank. [cross sectional, 2007]

      Determine if the variables in the UK biobank would be able to use different models to investigating malnutrition by mapping GLIM criteria, frailty by mapping it with two models 36 deficits and phenotype model. while sarcopenia will be matched with EWGSOP standard.

    2. Measuring the prevalence of the three conditions by applying the models in UK Biobank. [cross sectional, 2007]

      Measuring the estimate prevalence of malnutrition, frailty and sarcopenia in older people using UK Biobank database.

    Secondary Outcome Measures

    1. Determine the overlap between three conditions in the baseline assessment [cross sectional, 2007]

      Frailty overlaps with sarcopenia and malnutrition due to similarities of outcome related to body weight. In addition, frailty and sarcopenia have recently had set definitions and diagnostic criteria

    2. Compare prevalence results between different models [cross sectional, 2007]

      Estimating the frailty prevalence using two different measurement techniques the phenotype model with cumulative deficits model. In order to draw conclusion by comparing the results from each model.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    50 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    The inclusion criteria will be both genders, age more than or equal to 50 years old, who completed the touchscreen questionnaire, 24-hour recall and physical measurements to enable the identification of malnutrition, frailty and sarcopenia.

    Exclusion Criteria:

    Any participant who is under 50 or with incomplete information will be excluded.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Nada Almohaisen Manchester United Kingdom M1 5GB

    Sponsors and Collaborators

    • University of Manchester

    Investigators

    • Study Director: Sorrel Burden, University of Manchester

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Nada Adnan AlMohaisen, PhD Student, University of Manchester
    ClinicalTrials.gov Identifier:
    NCT04655456
    Other Study ID Numbers:
    • Manchester1
    First Posted:
    Dec 7, 2020
    Last Update Posted:
    Apr 30, 2021
    Last Verified:
    Apr 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Nada Adnan AlMohaisen, PhD Student, University of Manchester
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 30, 2021